Metabolic Health and Disease: A Role of Osteokines?

[1]  Xiaohui Zhang,et al.  Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National Health and Nutrition Examination Survey 2017–2018 , 2023, Osteoporosis International.

[2]  R. Eastell,et al.  Low Bone Turnover Associates with Lower Insulin Sensitivity in Newly Diagnosed Drug-naïve Persons with Type 2 Diabetes. , 2023, Journal of Clinical Endocrinology and Metabolism.

[3]  Qiu Zhang,et al.  Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies , 2023, BMC Endocrine Disorders.

[4]  N. Lu,et al.  RANKL Is Independently Associated with Increased Risks of Non-Alcoholic Fatty Liver Disease in Chinese Women with PCOS: A Cross-Sectional Study , 2023, Journal of clinical medicine.

[5]  Pengcheng Zhou,et al.  A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment , 2022, Frontiers in Endocrinology.

[6]  W. Leslie,et al.  Fracture risk and assessment in adults with cancer , 2022, Osteoporosis International.

[7]  P. Messa,et al.  Fibroblast growth factor 23 level modulates the hepatocyte’s alpha-2-HS-glycoprotein transcription through the inflammatory pathway TNFα/NFκB , 2022, Frontiers in Medicine.

[8]  D. Davis,et al.  Plasma Prostaglandin E2 Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation , 2022, Metabolites.

[9]  Xiaomeng Zhang,et al.  Effects of diabetes/hyperglycemia on peri-implant biomarkers and clinical and radiographic outcomes in patients with dental implant restorations: A systematic review and meta-analysis. , 2022, Clinical oral implants research.

[10]  Zhenjun Tian,et al.  Effects of different modes of exercise on skeletal muscle mass and function and IGF-1 signaling during early aging in mice. , 2022, The Journal of experimental biology.

[11]  M. Ahmeid,et al.  Evaluation of The Serum Level of Osteocalcin in Breast Cancer Patients, and Its Association with Estrogen and Progesterone Receptors , 2022, The Egyptian Journal of Hospital Medicine.

[12]  Haixiang Sun,et al.  Low levels of osteocalcin, but not CTX or P1NP, associated with nonalcoholic hepatic steatosis and steatohepatitis. , 2022, Diabetes & metabolism.

[13]  J. Jeong,et al.  Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR‐mediated inhibition of autophagy under hyperlipidemic conditions , 2022, Journal of cellular physiology.

[14]  Xiang Xue,et al.  The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis , 2022, Cells.

[15]  Zhanjun Jia,et al.  Inhibition of mPGES‐2 ameliorates NASH by activating NR1D1 via heme , 2022, Hepatology.

[16]  Yingying Zhao,et al.  HOXA13 promotes liver regeneration through regulation of BMP-7. , 2022, Biochemical and biophysical research communications.

[17]  Jingfang Liu,et al.  Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis , 2022, Osteoporosis International.

[18]  E. Witkowski,et al.  Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. , 2022, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[19]  Rui Li,et al.  Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway , 2022, Cellular and Molecular Life Sciences.

[20]  Miyang Luo,et al.  Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease , 2022, Frontiers in Immunology.

[21]  E. Lontchi-Yimagou,et al.  Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. , 2022, Diabetes research and clinical practice.

[22]  S. Kir,et al.  Inhibition of epidermal growth factor receptor suppresses parathyroid hormone‐related protein expression in tumours and ameliorates cancer‐associated cachexia , 2022, Journal of cachexia, sarcopenia and muscle.

[23]  Á. González-Rodríguez,et al.  Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool , 2022, medRxiv.

[24]  S. Cunningham,et al.  Obesity Incidence in U.S Children and Young Adults: A Pooled Analysis. , 2022, American journal of preventive medicine.

[25]  R. Kineman,et al.  Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. , 2022, The Journal of clinical endocrinology and metabolism.

[26]  G. Klein.  Transforming Growth Factor-Beta in Skeletal Muscle Wasting , 2022, International journal of molecular sciences.

[27]  Guoxiong Zhou,et al.  Identification of key genes and infiltrating immune cells among acetaminophen-induced acute liver failure and HBV-associated acute liver failure , 2022, Annals of translational medicine.

[28]  T. Zimmers,et al.  RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  H. Tian,et al.  Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease , 2021, Frontiers in Endocrinology.

[30]  L. Larsson,et al.  Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia , 2021, Science Translational Medicine.

[31]  Y. Liang,et al.  BMP-2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin-induced AC16 cell injury by inhibiting NLRP3 inflammasome-mediated pyroptosis. , 2021, Experimental and therapeutic medicine.

[32]  A. Boyce,et al.  Burosumab treatment for fibrous dysplasia. , 2021, Bone.

[33]  Sijia Wang,et al.  Type 2 Diabetes Is Causally Associated With Reduced Serum Osteocalcin: A Genomewide Association and Mendelian Randomization Study , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  L. Bonewald,et al.  Role of myokines and osteokines in cancer cachexia , 2021, Experimental biology and medicine.

[35]  V. Tillmann,et al.  Serum sclerostin concentration is associated with specific adipose, muscle and bone tissue markers in lean adolescent females with increased physical activity , 2021, Journal of Pediatric Endocrinology & Metabolism (JPEM).

[36]  Rachelle W Johnson,et al.  From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression , 2021, Frontiers in Oncology.

[37]  Courtney M. Mazur,et al.  Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones , 2021, Frontiers in Endocrinology.

[38]  J. Shepherd,et al.  Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018. , 2021, NCHS data brief.

[39]  M. Benatar,et al.  FGF23, a novel muscle biomarker detected in the early stages of ALS , 2021, Scientific Reports.

[40]  Y. Bao,et al.  Osteocalcin Alleviates Nonalcoholic Fatty Liver Disease in Mice through GPRC6A , 2021, International journal of endocrinology.

[41]  L. Ji,et al.  Sex-specific associations of serum insulin-like growth factor-1 with bone density and risk of fractures in Chinese patients with type 2 diabetes , 2021, Osteoporosis International.

[42]  Wei Huang,et al.  Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis , 2021, Annals of translational medicine.

[43]  H. Blau,et al.  Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength , 2020, Science.

[44]  Xin Gao,et al.  Osteocalcin and Non‐Alcoholic Fatty Liver Disease: Lessons From Two Population‐Based Cohorts and Animal Models , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  T. Komori.  Functions of Osteocalcin in Bone, Pancreas, Testis, and Muscle , 2020, International journal of molecular sciences.

[46]  Yaohui Nie,et al.  Skeletal muscle IGF-1 is lower at rest and after resistance exercise in humans with obesity , 2020, European Journal of Applied Physiology.

[47]  P. Delafontaine,et al.  Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy , 2020, Cells.

[48]  Yichao Wang,et al.  Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis , 2020, Journal of Physiology and Biochemistry.

[49]  S. Manolagas.  Osteocalcin promotes bone mineralization but is not a hormone , 2020, PLoS genetics.

[50]  Shan Li,et al.  RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet , 2020, BioMed research international.

[51]  T. Ishimoto,et al.  Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass , 2020, PLoS genetics.

[52]  L. Bonewald,et al.  The Osteocyte: New Insights. , 2020, Annual review of physiology.

[53]  T. Nakashima,et al.  RANKL biology: bone metabolism, the immune system, and beyond , 2020, Inflammation and Regeneration.

[54]  H. Yagita,et al.  Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice. , 2020, Human molecular genetics.

[55]  A. Baierl,et al.  Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis , 2020, Wiener klinische Wochenschrift.

[56]  Youming Li,et al.  Role of Hepatokines in Non-alcoholic Fatty Liver Disease , 2019, Journal of translational internal medicine.

[57]  Nam Hoon Kim,et al.  Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS). , 2019, Bone.

[58]  H. Yagita,et al.  An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. , 2019, Human molecular genetics.

[59]  P. Jakobsson,et al.  Urinary prostaglandin D2 and E2 metabolites associate with abdominal obesity, glucose metabolism, and triglycerides in obese subjects. , 2019, Prostaglandins & other lipid mediators.

[60]  Cassandra R Diegel,et al.  An osteocalcin-deficient mouse strain without endocrine abnormalities , 2019, bioRxiv.

[61]  L. Bonewald,et al.  Molecular Mechanisms Responsible for the Rescue Effects of Pamidronate on Muscle Atrophy in Pediatric Burn Patients , 2019, Front. Endocrinol..

[62]  G. McConell,et al.  Undercarboxylated Osteocalcin Improves Insulin‐Stimulated Glucose Uptake in Muscles of Corticosterone‐Treated Mice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  E. Hesse,et al.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. , 2019, JCI insight.

[64]  Y. Maehara,et al.  Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma , 2019, Journal of Gastroenterology.

[65]  L. Bonewald.  Use it or lose it to age: A review of bone and muscle communication. , 2019, Bone.

[66]  J. Stevens,et al.  Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. , 2019, Metabolic syndrome and related disorders.

[67]  Z. Kamenov,et al.  Prediabetes is Characterized by Higher FGF23 Levels and Higher Prevalence of Vitamin D Deficiency Compared to Normal Glucose Tolerance Subjects , 2018, Hormone and Metabolic Research.

[68]  A. Schürmann,et al.  Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model , 2018, Scientific Reports.

[69]  K. Avin,et al.  Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. , 2018, American journal of physiology. Endocrinology and metabolism.

[70]  Y. Bao,et al.  The association of serum FGF23 and non‐alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients , 2018, Clinical and experimental pharmacology & physiology.

[71]  A. Kasprzak,et al.  Insulin-Like Growth Factor (IGF) System in Liver Diseases , 2018, International journal of molecular sciences.

[72]  P. Messa,et al.  FGF23 and Fetuin-A Interaction in the Liver and in the Circulation , 2018, International journal of biological sciences.

[73]  Xianqun Fan,et al.  Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[74]  C. Vilos,et al.  TGF-β requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy , 2017, Biological chemistry.

[75]  G. Karsenty,et al.  Molecular bases of the crosstalk between bone and muscle. , 2017, Bone.

[76]  B. Herrera,et al.  BMP Signalling at the Crossroad of Liver Fibrosis and Regeneration , 2017, International journal of molecular sciences.

[77]  R. Tomlinson,et al.  Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes , 2017, Proceedings of the National Academy of Sciences.

[78]  Mark L. Johnson,et al.  Crosstalk Between MLO‐Y4 Osteocytes and C2C12 Muscle Cells Is Mediated by the Wnt/β‐Catenin Pathway , 2017, JBMR plus.

[79]  ChangZhen Liu,et al.  Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer , 2017, Scientific Reports.

[80]  L. Bonewald,et al.  Osteocytes Acidify Their Microenvironment in Response to PTHrP In Vitro and in Lactating Mice In Vivo , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  Y. Bao,et al.  Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus , 2017, Cardiovascular Diabetology.

[82]  Li Peng,et al.  High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients , 2017, Oncotarget.

[83]  A. Teschendorff,et al.  Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer , 2016, Oncotarget.

[84]  Hai-ying Liu,et al.  Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis , 2016, Oncotarget.

[85]  M. Wolf,et al.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. , 2016, Kidney international.

[86]  L. Rodríguez-Mañas,et al.  Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. , 2016, Journal of the American Medical Directors Association.

[87]  G. Karsenty,et al.  Osteocalcin is necessary and sufficient to maintain muscle mass in older mice , 2016, Molecular metabolism.

[88]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[89]  R. de Cabo,et al.  Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise. , 2016, Cell metabolism.

[90]  S. Dooley,et al.  TGF‐β signalling and liver disease , 2016, The FEBS journal.

[91]  Tae Woo Jung,et al.  Implication of hepatokines in metabolic disorders and cardiovascular diseases , 2016, BBA clinical.

[92]  B. Spiegelman,et al.  PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer. , 2016, Cell metabolism.

[93]  Nicolas A. Dumont,et al.  Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles. , 2016, American journal of physiology. Cell physiology.

[94]  E. Kang,et al.  Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. , 2016, The Journal of clinical endocrinology and metabolism.

[95]  T. Watabe,et al.  Bone Morphogenetic Proteins. , 2016, Cold Spring Harbor perspectives in biology.

[96]  T. Guise,et al.  Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. , 2016, Seminars in cell & developmental biology.

[97]  J. Kountouras,et al.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease , 2016, Journal of Bone and Mineral Metabolism.

[98]  W. Jia,et al.  Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels , 2015, Acta Pharmacologica Sinica.

[99]  M. Sandri,et al.  BMPs and the muscle-bone connection. , 2015, Bone.

[100]  Wenjun Xie,et al.  Excess TGF-β mediates muscle weakness associated with bone metastases in mice , 2015, Nature Medicine.

[101]  L. Bonewald,et al.  Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone , 2015, PloS one.

[102]  N. Sims,et al.  Quantifying the osteocyte network in the human skeleton. , 2015, Bone.

[103]  J. Sara,et al.  Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients , 2015, Cardiovascular Diabetology.

[104]  C. Creighton,et al.  FGF23 promotes prostate cancer progression , 2015, Oncotarget.

[105]  F. Tinahones,et al.  Parathyroid Hormone-Related Protein, Human Adipose-Derived Stem Cells Adipogenic Capacity and Healthy Obesity. , 2015, The Journal of clinical endocrinology and metabolism.

[106]  L. Bonewald,et al.  Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation , 2015, Cell cycle.

[107]  K. Lau,et al.  Osteocyte-Derived Insulin-Like Growth Factor I Is Not Essential for the Bone Repletion Response in Mice , 2015, PloS one.

[108]  H. Fukasawa,et al.  Plasma levels of fibroblast growth factor‐23 are associated with muscle mass in haemodialysis patients , 2014, Nephrology.

[109]  M. Ferron,et al.  Regulation of energy metabolism by the skeleton: osteocalcin and beyond. , 2014, Archives of biochemistry and biophysics.

[110]  S. Ge,et al.  Potential Roles of BMP9 in Liver Fibrosis , 2014, International journal of molecular sciences.

[111]  B. Spiegelman,et al.  Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia , 2014, Nature.

[112]  V. Borba,et al.  Osteocalcin, energy and glucose metabolism. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[113]  S. Dooley,et al.  Potential Roles of Bone Morphogenetic Protein (BMP)-9 in Human Liver Diseases , 2014, International journal of molecular sciences.

[114]  Fenfen Liang,et al.  Activated Effects of Parathyroid Hormone-Related Protein on Human Hepatic Stellate Cells , 2013, PloS one.

[115]  Stefano Piccolo,et al.  BMP signaling controls muscle mass , 2013, Nature Genetics.

[116]  M. Sandri,et al.  Mechanisms regulating skeletal muscle growth and atrophy , 2013, The FEBS journal.

[117]  M. Arenas,et al.  Novel Role of Parathyroid Hormone-Related Protein in the Pathophysiology of the Diabetic Kidney: Evidence from Experimental and Human Diabetic Nephropathy , 2013, Journal of diabetes research.

[118]  Stella Lukas Yani,et al.  Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects , 2013, Biogerontology.

[119]  Huixia Li,et al.  Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway. , 2013, Endocrinology.

[120]  F. Kronenberg,et al.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus , 2013, Nature Medicine.

[121]  L. Bonewald,et al.  Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice. , 2013, Bone.

[122]  Y. Rhee,et al.  Effect of liver dysfunction on circulating sclerostin , 2013, Journal of Bone and Mineral Metabolism.

[123]  L. Bonewald,et al.  Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation. , 2012, Recent patents on biotechnology.

[124]  E. Kastritis,et al.  Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy , 2012, International journal of cancer.

[125]  R. Rizzoli,et al.  Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. , 2012, Bone.

[126]  J. Wysolmerski.  Parathyroid hormone-related protein: an update. , 2012, The Journal of clinical endocrinology and metabolism.

[127]  K. Govoni.  Insulin-like growth factor-I molecular pathways in osteoblasts: potential targets for pharmacological manipulation. , 2012, Current molecular pharmacology.

[128]  R. Nuti,et al.  Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[129]  C. O’Brien,et al.  Osteocyte RANKL: New insights into the control of bone remodeling , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[130]  M. McKee,et al.  Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. , 2012, Bone.

[131]  J. A. Garcia-Salcedo,et al.  Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[132]  F. Karadağ,et al.  The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer , 2012, International Journal of Clinical Oncology.

[133]  R. Edwards,et al.  Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.

[134]  F. Eren,et al.  Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration , 2011, Scandinavian journal of clinical and laboratory investigation.

[135]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[136]  L. Bonewald,et al.  The Amazing Osteocyte , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[137]  E. Karapanagiotou,et al.  Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients , 2010, Medical oncology.

[138]  Avijit Lahiri,et al.  Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. , 2010, Journal of the American College of Cardiology.

[139]  I. Legakis,et al.  Positive Correlation of PTH-Related Peptide with Glucose in Type 2 Diabetes , 2009, Experimental diabetes research.

[140]  D. Chianese,et al.  Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? , 2008, Journal of Translational Medicine.

[141]  T. Luedde,et al.  Bone Morphogenetic Protein 7 is Elevated in Patients with Chronic Liver Disease and Exerts Fibrogenic Effects on Human Hepatic Stellate Cells , 2007, Digestive Diseases and Sciences.

[142]  A. Gill,et al.  Elevated serum FGF23 concentrations in plasma cell dyscrasias. , 2006, Bone.

[143]  D. Giannella‐Neto,et al.  Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. , 2006, World journal of gastroenterology.

[144]  H. Tilg,et al.  The RANKL/OPG system and bone mineral density in patients with chronic liver disease. , 2005, Journal of hepatology.

[145]  J. Reeve,et al.  The FASEB Journal express article 10.1096/fj.05-4221fje. Published online August 25, 2005. ©2005 FASEB , 2022 .

[146]  K. Esser,et al.  Wnt/β-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy , 2005 .

[147]  A. Rivas-Estilla,et al.  PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. , 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[148]  Wei-Chun Chang,et al.  Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report. , 2002, Japanese journal of clinical oncology.

[149]  K. Sjögren,et al.  Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[150]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[151]  K. Feingold,et al.  Parathyroid hormone-related protein is induced in the adult liver during endotoxemia and stimulates the hepatic acute phase response. , 1997, Endocrinology.

[152]  C. Bondy,et al.  Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. , 1995, Endocrinology.